Apellis Pharmaceuticals Inc (APLS)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$25.21

Buy

$26.20

arrow-up$0.265 (+1.06%)

Prices updated at 12 Dec 2025, 22:53 EST

Prices minimum 15 mins delay

Prices in USD

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. Gerald L. Chan, Sc.D.

CEO

Dr. Cedric Francois, M.D.

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

710

Head office

100 Fifth Avenue

Waltham

United States

02451

+1 617 977-5700

investors@apellis.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Craig A. Wheeler Independent Director	-
Ms. Keli Walbert Independent Director	-
Mr. David Acheson Executive Vice President, Commercial	-
Mr. Alec Machiels Independent Director	0.09m
Dr. Gerald L. Chan, Sc.D. Chairman of the Board	0.10m
Ms. Stephanie Monaghan O’Brien Independent Director	0.09m
Mr. Timothy E. Sullivan Chief Financial Officer and Treasurer	0.53m
Dr. Cedric Francois, M.D. Director, Chief Executive Officer and President	0.79m
Mr. Pascal Deschatelets, PhD Chief Scientific Officer	-
Mr. David Watson General Counsel and Secretary	0.51m
Mr. A. Sinclair Dunlop Independent Director	0.08m
Mr. Paul Fonteyne, M.S. Independent Director	0.09m
Ms. Nur Nicholson Chief Technical Operations Officer	-
Mr. James George Chopas Vice President, Corporate Controller, Treasurer and Chief Accounting Officer	-
Mr. Mark Jeffrey DeLong Chief Business and Strategy Officer	-
Dr. Caroline Baumal, M.D. Chief Medical Officer	0.61m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Wellington Management Group, LLP	15,599,529
venBio Select Advisor LLC	12,222,222
Vanguard Group Inc	10,154,751
Morgan Stanley - Brokerage Accounts	9,643,248
Wellington Management Company LLP	9,290,960

Director dealings

Date chevron-l-regular chevron-r-regular	Action
31 Dec 2024	-
31 Dec 2024	-
31 Dec 2024	-
31 Dec 2024	-
23 Dec 2024	-
11 Dec 2024	-
01 Nov 2024	-
27 Sep 2024	-
27 Sep 2024	-
23 Sep 2024	-
23 Sep 2024	-
16 Sep 2024	-
16 Sep 2024	-
16 Sep 2024	-
03 Sep 2024	-
12 Aug 2024	-
12 Aug 2024	-
28 Jun 2024	-
28 Jun 2024	-
21 Jun 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.